Two early case reports23,24 documented severe reactions to the combination of stimulants and MAOIs. A report from 196523 described a case of hypertensive crisis and cerebral hemorrhage from the combination of dextroamphetamine and phenelzine. A case from 196924 reported nonfatal hyperpyrexia after combined treatment with dextroamphetamine and tranylcypromine.
Later cases have documented more successful treatment with this medication combination. Feighner and colleagues25 treated a series of 13 patients with treatment-resistant MDD using either dextroamphetamine or methylphenidate along with an MAOI and found the combination safe and effective, with hypotension the most common adverse effect. Fawcett and colleagues26 treated a series of 32 patients with treatment-resistant MDD with either pemoline up to 112.5 mg/d or dextroamphetamine up to 40 mg/d in combination with tranylcypromine, phenelzine, isocarboxazid, or pargyline (pemoline and pargyline are no longer manufactured). They, too, found the combination to be effective and medically safe, with no episodes of hypertensive crisis.26 Three other case reports have documented safe and effective use of combining MAOIs and stimulants: 1 using dextroamphetamine 10 mg/d combined with tranylcypromine 40 mg/d for treatment-resistant MDD,27 1 combining methylphenidate 40 mg/d and moclobemide 600 mg/d for comorbid MDD and ADHD,28 and another using phenelzine 45 mg/d and methylphenidate 17.5 mg/d for comorbid MDD and ADHD.29 Feinberg30 reported a successful case of treatment of MDD and ADHD using the combination of tranylcypromine 50 mg/d and methylphenidate 45 mg/d, again with no adverse medical outcomes. A less favorable medical outcome was documented by Bodner et al,31 who reported the case of a patient who developed serotonin syndrome while being treated with the combination of isocarboxazid 30 mg/d, trazodone 150 mg/d, and methylphenidate 10–20 mg/d, although it was not possible to determine to what degree, if any, the stimulant was a factor in this adverse event.
Thomas et al32 provide a thorough review of the literature on combining MAOIs with potentially contraindicated medications for treatment-resistant MDD, including SSRIs and stimulants. Their review includes the only published case to date on use of the transdermal selegiline patch with an MAOI, reporting 1 case of safe and beneficial treatment using the selegiline transdermal patch 12 mg/d along with amphetamine. This review32 also includes a case using phenelzine 60 mg/d with methylphenidate (as well as desipramine 75 mg/d and trazodone 300 mg/d) that resulted in hypotension and tachycardia.